Gilead Sciences (NASDAQ:GILD) Price Target Raised to $161.00

Gilead Sciences (NASDAQ:GILD) had its price objective upped by Daiwa Securities Group from $129.00 to $161.00 in a report issued on Wednesday morning,MarketScreener reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently weighed in on the company. Sanford C. Bernstein reissued an “outperform” rating and issued a $160.00 price target on shares of Gilead Sciences in a report on Wednesday, February 11th. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research note on Thursday, January 8th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Oppenheimer lifted their price target on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. Finally, Leerink Partners upped their price objective on shares of Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. Twenty-three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $156.72.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $148.95 on Wednesday. The company has a current ratio of 1.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $184.91 billion, a P/E ratio of 22.00, a price-to-earnings-growth ratio of 1.88 and a beta of 0.36. The firm has a 50-day moving average price of $136.10 and a two-hundred day moving average price of $124.77. Gilead Sciences has a twelve month low of $93.37 and a twelve month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the prior year, the firm earned $1.90 earnings per share. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, research analysts expect that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.2%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s dividend payout ratio is 46.68%.

Insider Activity

In other news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the transaction, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of the company’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the completion of the transaction, the chief executive officer owned 613,912 shares of the company’s stock, valued at $92,086,800. This trade represents a 15.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 299,280 shares of company stock worth $42,487,570. Company insiders own 0.27% of the company’s stock.

Institutional Trading of Gilead Sciences

Several large investors have recently modified their holdings of the business. Paulson Wealth Management Inc. boosted its holdings in Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares during the last quarter. Essex Financial Services Inc. boosted its stake in shares of Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after buying an additional 71 shares during the last quarter. Alpha Cubed Investments LLC grew its position in shares of Gilead Sciences by 1.1% during the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after buying an additional 75 shares in the last quarter. Personal CFO Solutions LLC increased its stake in shares of Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 76 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC raised its holdings in Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after acquiring an additional 76 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead highlighted a twice-yearly HIV prevention injection with reported 99.9% efficacy (executive interview), reinforcing the company’s long-acting HIV/IP prevention market potential and upside to future sales if uptake and approvals follow. Johanna Mercier on Gilead’s HIV prevention innovation
• Positive Sentiment: New Phase 3 ARTISTRY-1 and ARTISTRY-2 data show the investigational single-tablet bictegravir/lenacapavir (BIC/LEN) maintained virological suppression when patients switched regimens — strengthens pipeline value and switch-market potential. Gilead’s Single-Tablet Regimen Maintained Virological Suppression
• Positive Sentiment: Daiwa raised its price target to $161 and kept an “outperform” rating, signaling buy-side confidence and giving shares technical/analyst momentum. Daiwa Securities Adjusts Price Target on Gilead Sciences
• Positive Sentiment: UBS reiterated a Buy with a $175 target, citing the advancing long-acting HIV franchise — another supportive analyst endorsement for upside. Gilead Sciences: Advancing Long-Acting HIV Franchise
• Positive Sentiment: Zacks issued a series of upward revisions to Gilead’s FY2026–FY2028 and multiple quarterly EPS forecasts (raises across 2026–2028), which supports higher medium-term earnings expectations. Zacks Research GILD Estimates
• Neutral Sentiment: Coverage pieces note Gilead has been outperforming the healthcare sector recently and analysts remain optimistic — supports momentum but is descriptive rather than new fundamental news. Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?
• Neutral Sentiment: Industry/peer updates such as Kymera’s results were reported but are not directly material to Gilead’s near-term outlook. Kymera Therapeutics Q4 Highlights
• Negative Sentiment: Zacks trimmed its Q3 2026 EPS estimate slightly (from $2.34 to $2.30) — a small near-term downgrade within otherwise stronger multi-year raises; worth monitoring for quarterly variability. Zacks Lowers Q3 2026 Estimate
• Negative Sentiment: Merck reported promising Phase 3 results for a two-drug HIV regimen that matched Gilead’s Biktarvy, representing competitive pressure if approved. Investors should monitor regulatory outcomes and market-share implications. Merck’s New HIV Drug Shows Promise

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.